Q2Pharma
Prevention of Multidrug-resistant Bacterial Infections
Company Overview
Snapshot
Founded in November 2015 by Jacob BenArie, Menachem Shoham, and Yaron Shoham, Q2Pharma operates with 1–10 employees. The company has raised $800,000 across one funding round from two investors. In March 2017, Q2Pharma partnered with Case Western Reserve University to develop antivirulence agents.
Business overview
Q2Pharma specializes in the development of small-molecule drugs designed to combat multi-drug-resistant (MDR) bacteria. The company's core technology focuses on antivirulent agents, such as its lead compound F19, which inhibits bacterial toxin release to enhance the immune system's ability to resolve infections. These drugs are intended for use either in conjunction with existing antibiotics or as standalone treatments, serving the global pharmaceutical and life sciences markets within the Health Tech & Life Sciences sector.
Strategic signal
In October 2018, researchers announced that Q2Pharma's technology could cure drug-resistant infections without relying solely on antibiotics. This signals a significant advancement in addressing the global challenge of antibiotic resistance, indicating the potential for a new class of therapeutics that disarm 'superbugs' by inhibiting virulence rather than directly killing bacteria, thereby preserving the efficacy of existing antibiotics and offering a novel approach to infectious disease treatment.
Log in to access full profile ›Company Intelligence Q&A
- What is Q2Pharma's primary focus?
- Q2Pharma specializes in developing small-molecule drugs for the prevention and treatment of multidrug-resistant bacterial infections.
- When was Q2Pharma founded?
- Q2Pharma was founded in November 2015.
- Who are the co-founders of Q2Pharma?
- The co-founders of Q2Pharma are Jacob BenArie, Menachem Shoham, and Yaron Shoham.
- What is the status of Q2Pharma's operations?
- Q2Pharma ceased to operate in February 2024.
- What was a key partnership for Q2Pharma?
- In March 2017, Q2Pharma partnered with Case Western Reserve University to develop antivirulence agents aimed at disarming superbugs.